HUTCHISON CHINA MED. Stock London S.E.
Stocks
Pharmaceuticals
OTC Markets Traded| Market Cap | 2.31B 2.06B 1.9B 1.72B 3.22B 219B 3.28B 22.65B 9.09B 115B 8.65B 8.47B 363B | P/E 2026 * |
42.7x | P/E 2027 * | 38.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1.74B 1.56B 1.43B 1.3B 2.43B 165B 2.47B 17.1B 6.86B 86.93B 6.53B 6.39B 274B | EV / Sales 2026 * |
2.78x | EV / Sales 2027 * | 2.4x |
| Free-Float |
61.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HUTCHISON CHINA MED.
| 1 day | -2.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Chig Fung Cheng
CEO | Chief Executive Officer | 59 | 2025-08-24 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 61 | 2021-12-31 |
Karen Atkin
COO | Chief Operating Officer | 60 | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Edith Shih
BRD | Director/Board Member | 74 | 2005-12-31 |
Chig Fung Cheng
BRD | Director/Board Member | 59 | 2010-12-31 |
Wei Guo Su
BRD | Director/Board Member | 68 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.79% | -0.24% | - | - | 2.31B | |
| +3.19% | +11.31% | +67.86% | +150.58% | 1,263B | |
| -0.73% | +3.56% | +44.51% | +85.81% | 658B | |
| +1.41% | +3.24% | +29.22% | +107.83% | 521B | |
| +0.42% | +3.20% | +54.15% | +67.18% | 391B | |
| +2.18% | +2.93% | +73.30% | +45.62% | 369B | |
| +1.12% | +4.52% | +35.30% | +58.08% | 307B | |
| +6.96% | +8.86% | +11.27% | +36.62% | 290B | |
| +1.15% | +6.09% | +59.59% | +77.06% | 252B | |
| +3.06% | +9.38% | +44.11% | +119.47% | 212B | |
| Average | +1.28% | +5.90% | +46.59% | +83.14% | 473.55B | |
| Weighted average by Cap. | +1.19% | +6.60% | +50.88% | +98.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 627M 561M 516M 468M 874M 59.5B 891M 6.16B 2.47B 31.3B 2.35B 2.3B 98.7B | 699M 626M 576M 522M 975M 66.35B 993M 6.87B 2.76B 34.9B 2.62B 2.57B 110B |
| Net income | 60.99M 54.63M 50.25M 45.53M 85.1M 5.79B 86.7M 599M 241M 3.05B 229M 224M 9.61B | 71.69M 64.21M 59.06M 53.51M 100M 6.81B 102M 704M 283M 3.58B 269M 263M 11.29B |
| Net Debt | -565M -506M -465M -422M -788M -53.62B -803M -5.55B -2.23B -28.21B -2.12B -2.07B -88.96B | -629M -564M -519M -470M -878M -59.76B -895M -6.18B -2.48B -31.44B -2.36B -2.31B -99.14B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
